Clinical trials: HPV Infection
HPV Infection, Cervical Cancer
HPV-Based Screen-and-Treat Demonstration Project in Lilongwe
The purpose of this study is to assess completion and performance of the following novel invasive cervical cancer (ICC) screen-and-treat algorithm among 625 HIV-positive women in Lilongwe, Malawi: 1) rapid testing of…
- Conditions
- HPV Infection, Cervical Cancer, HIV Infections
- Trial name
- NCT04092257
- Testing
- VIA and thermocoagulation
- Where
- Malawi
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
HPV Vaccination, Vaccine; Uptake
PREVENT HPV-Related Cancers - BootCamp Translation
This study will serve as one of the first to develop and test the effectiveness of strategies to promote HPV vaccination among diverse rural parents and caregivers of children ages 9-17 years in the Mountain West.
- Conditions
- HPV Vaccination, Vaccine; Uptake, Vaccination; Series Completion
- Trial name
- PREVENT (NCT06290206)
- Testing
- PREVENT - BCT
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Utah
HPV - Anogenital Human Papilloma Virus Infection
Screening for Cervical Intraepithelial Neoplasia Using Self-collected Menstrual Blood
The purpose of this study is to investigate the feasibility and efficacy of assessing HR-HPV DNA and HPV E6/E7 mRNA via self-collected menstrual blood in a smart menstrual pad.
- Trial name
- NCT03638427
- Testing
- Menstrual Blood Analysis (Menstrual Blood Analysis)
- Where
- United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Stanford University
Cervical Cancers, Vulvar Cancer
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
This study will evaluate the immunogenicity and tolerability of V503 (a multivalent human papillomavirus [HPV] L1 virus-like particle [VLP] vaccine) in preadolescent and adolescent participants between 9 and 15 years old and…
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, Genital Lesions
- Trial name
- NCT00943722
- Testing
- V503
- Volunteers
- 3,074 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus (HPV) Infection
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.
Cervical cancer is the second most common cancer among women worldwide. Approximately 500 000 new cases are reported each year worldwide, from which 83% occur in developing countries.
- Trial name
- NCT00481767
- Testing
- Cervarix
- Where
- 2 sites in Senegal, Tanzania
- Volunteers
- 676 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV Infections
Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)
A study to test the safety and effectiveness of Quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine against combined incidence of HPV 6/11/16/18-related persistent infection and vaccine type-specific genital disease among…
- Trial name
- NCT00834106
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 3,006 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV Infections
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
The study evaluates the immunogenicity, safety and tolerability of V501 in preadolescent females
- Trial name
- NCT00411749
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV Infections
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
A study to evaluate the efficacy, immunogenicity, safety and tolerability of V501 in adult women
- Trial name
- NCT00378560
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 1,021 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus (HPV) Infection
GARDASIL Reexamination Study (V501-059)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of Gardasil through collecting…
- Trial name
- NCT01062074
- Volunteers
- 3,605 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV 16 Infection
Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)
Subjects received HPV 16 L1 VLP vaccine or placebo (1:1 ratio). Endpoints included efficacy, immunogenicity, and safety.
- Trial name
- NCT00365378
- Testing
- Comparator: HPV 16 L1 Vaccine
- Volunteers
- 2,409 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV Infections
An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)
To prove that quadrivalent HPV (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine is generally safe and well tolerated in the Chinese population.
- Trial name
- NCT00635830
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC